1887

Chapter 89 : Human T-Cell Lymphotropic Virus Types 1 and 2

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in
Zoomout

Human T-Cell Lymphotropic Virus Types 1 and 2, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555815905/9781555813642_Chap89-1.gif /docserver/preview/fulltext/10.1128/9781555815905/9781555813642_Chap89-2.gif

Abstract:

Human T-cell leukemia virus type 1 (HTLV-1) was reported in 1980 by Bernard Poiesz and Robert Gallo as the first retrovirus shown to be pathogenic to humans. As can be surmised from the description of some mechanisms of pathogenesis, the diseases associated with human T-cell leukemia virus (HTLV) infection have inflammatory and/or proliferative attributes. HTLV-1 and HTLV-2 diseases are usually classified as malignant or nonmalignant clinical presentations. Diagnosis of uveitis is based on clinical presentation and the presence of antibodies to HTLV-1 as well as the confirmation of proviral DNA by PCR. Sjögren’s syndrome is an autoimmune disorder complete with the expression of anticentromere antibodies, while the antibodies expressed with sicca syndrome are to HTLV-1. Skin lesions constitute the most common initial clinical presentation of disease and can appear as papules, nodules, infiltrated plaques, tumors, or erythroderma. The treatment of adult T-cell leukemia/lymphoma (ATL) consists of chemotherapy, alpha interferon, and zidovudine. The main cause of death is disease progression combined with hypercalcemia and septicemia. The detection of HTLV-1 and -2 relies on the presence of serum or plasma antibodies and proviral DNA. Enzyme-linked immunosorbent assays (ELISAs), Western immunoblots, and radioimmunoprecipitation assays (RIPAs) are used to confirm repeatedly reactive or inconclusive findings. The interpretation of PCR-restriction fragment length polymorphism findings is based on the comparison to the banding patterns of known standards. HTLV-1- and HTLV-2-seropositive patients should be counseled about prevention of transmission. Patients are advised to use condoms during sexual intercourse and are prohibited from donating blood or blood products.

Citation: Nyland S, Loughran T, Ugen K. 2006. Human T-Cell Lymphotropic Virus Types 1 and 2, p 798-802. In Detrick B, Hamilton R, Folds J (ed), Manual of Molecular and Clinical Laboratory Immunology, 7th Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815905.ch89

Key Concept Ranking

Restriction Fragment Length Polymorphism
0.453739
0.453739
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of FIGURE 1
FIGURE 1

Flowchart for HTLV-1 and -2 detection and discrimination. For patients with combined clinical presentation and risk factors, detection of HTLV-1 and -2 infection begins with ELISA testing. When both ELISA results are negative (—), it is recommended that follow-up include documentation of other possible causes for the clinical presentation, as well as additional testing if other causes are ruled out. Repeatedly reactive (+) results must be confirmed by Western blot analysis and then analyzed by PCR if indicated. Indeterminate (?) or reactive ELISA results that are nonreactive on Western blotting should be confirmed by RIPA. Repeatedly indeterminate results can be clarified by PCR-related methods. RFLP, restriction fragment length polymorphism.

Citation: Nyland S, Loughran T, Ugen K. 2006. Human T-Cell Lymphotropic Virus Types 1 and 2, p 798-802. In Detrick B, Hamilton R, Folds J (ed), Manual of Molecular and Clinical Laboratory Immunology, 7th Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815905.ch89
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555815905.ch89
1. Agadjanyan, M. G.,, K. F. Ugen,, B. Wang,, W. V. Williams, and , D. B. Weiner. 1994. Identification of an 80-kilodalton membrane glycoprotein important for human T-cell leukemia virus type I and type II syncytium formation and infection. J. Virol. 68:485493.
2. Beby-Defaux, A.,, F. Frugier,, A. Bourgoin,, D. Moynet,, C. Hajjar,, S. Sainte-Foie,, B. Guillemain, and , G. Agius. 1999. Nucleotide sequence analysis of human T-cell lym-photropic virus type I pX and LTR regions from patients with sicca syndrome. J. Med. Virol. 59:245255.
3. Brady, J. N. 1996. Biology of HTLV-I: host cell interactions, p. 79112. In P. Hollsberg and , D. A. Hafler (ed.), Human T-Cell Lymphotropic Virus Type I. John Wiley & Sons, Inc., New York, N.Y.
4. Carrington, C. V. F., and , T. F. Schulz. 1996. Virology of HTLV-I infection, p. 113139. In P. Hollsberg and , D. A. Hafler (ed.), Human T-Cell Lymphotropic Virus Type I. John Wiley & Sons, Inc., New York, N.Y.
5. Cereseto, A.,, J. C. Mulloy, and , G. Franchini. 1996. Insights on the pathogenicity of human T-lymphotropic/leukemia virus types I and II. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 13(Suppl. 1):S69S75.
6. Gessain, A. 1996. Epidemiology of HTLV-I and associated diseases, p. 3365. In P. Hollsberg and , D. A. Hafler (ed.), Human T-Cell Lymphotropic Virus Type I. John Wiley & Sons, Inc., New York, N.Y.
7. Good, L.,, S. B. Maggirwar, and , S. C. Sun. 1996. Activation of the IL-2 gene promoter by HTLV-I Tax involves induction of NF-AT complexes bound to the CD28-responsive element. EMBO J. 15:37443750.
8. Hall, W. W.,, R. Ishak,, S. W. Zhu,, P. Novoa,, N. Eiraku,, H. Takahashi,, C. Ferreira Mda,, V. Azevedo,, M. O. Ishak,, C. Ferreira Oda,, C. Monken, and , T. Kurata. 1996. Human T lymphotropic virus type II (HTLV-II): epidemiology, molecular properties, and clinical features of infection. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 13(Suppl. 1):S204S214.
9. Hall, W. W.,, T. Kubo,, S. Ijichi,, H. Takahashi, and , S. W. Zhu. 1994. Human T cell leukemia/lymphoma virus, type II (HTLV-II): emergence of an important newly recognized pathogen. Semin. Virol. 5:165178.
10. Ikeda, K.,, M. Oka,, Y. Yamada,, H. Soda,, M. Fukuda,, A. Kinoshita,, K. Tsukamoto,, Y. Noguchi,, H. Isomoto,, F. Takeshima,, K. Murase,, S. Kamihira,, M. Tomonaga, and , S. Kohno. 1999. Adult T-cell leukemia cells overexpress the multidrug-resistance protein (MRP) and lung-resistance protein (LRP) genes. Int. J. Cancer 82:599604.
11. La Grenade, L.,, A. Manns,, V. Fletcher,, D. Derm,, C. Carberry,, B. Hanchard,, E. M. Maloney,, B. Cranston,, N. P. Williams,, R. Wilks,, E. C. Kang, and , W. A. Blattner. 1998. Clinical, pathologic, and immunologic features of human T-lymphotrophic virus type I-associated infective dermatitis in children. Arch. Dermatol. 134:439444.
12. Levin, M. C.,, S. M. Lee,, F. Kalume,, Y. Morcos,, F. C. Dohan, Jr.,, K. A. Hasty,, J. C. Callaway,, J. Zunt,, D. Desiderio, and , J. M. Stuart. 2002. Autoimmunity due to molecular mimicry as a cause of neurological disease. Nat. Med. 8:509513.
13. Manel, N.,, F. J. Kim,, S. Kinet,, N. Taylor,, M. Sitbon, and , J. L. Battini. 2003. The ubiquitous glucose transporter GLUT-1 is a receptor for HTLV Cell 115:449459.
14. Manns, A.,, M. Hisada, and , L. La Grenade. 1999. Human T-lymphotropic virus type I infection. Lancet 353:19511958.
15. Muller, K.,, M. Zak,, S. Nielsen,, E. K. Pedersen,, P. de Nully, and , K. Bendtzen. 1997. Interleukin-1 receptor antagonist in neonates, children and adults, and in patients with pauci- and polyarticular onset juvenile chronic arthritis. Clin. Exp. Rheumatol. 15:439444.
16. Murphy, E. L.,, S. A. Glynn,, J. Fridey,, J. W. Smith,, R. A. Sacher,, C. C. Nass,, H. F. Ownby,, D. J. Wright, and , G. J. Nemo. 1999. Increased incidence of infectious diseases during prospective follow-up of human T-lymphotropic virus type II- and I-infected blood donors. Retrovirus Epidemiology Donor Study. Arch. Intern. Med. 159:14851491.
17. Nyland, S. B.,, C. Cao,, Y. Bai,, T. P. Loughran, and , K. F. Ugen. 2003. Modulation of infection and type 1 cytokine expression parameters by morphine during in vitro coinfec-tion with human T-cell leukemia virus type I and HIV-1. J. Acquir. Immune Defic. Syndr. 32:406416.
18. Osame, M. 2002. Pathological mechanisms of human T-cell lymphotropic virus type I-associated myelopathy (HAM/TSP). J. Neurovirol. 8:359364.
19. Poiesz, B. J.,, E. W. Ruscetti,, A. F. Gazdar,, P. A. Bunn,, J. D. Minna, and , R. C. Gallo. 1980. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc. Natl. Acad. Sci. USA 77:74157419.
20. Pombo De Oliveira, M. S.,, P. Loureiro,, A. Bittencourt,, C. Chiattone,, D. Borducchi,, S. M. De Carvalho,, H. S. Barbosa,, M. Rios,, A. Sill,, F. Cleghorn,, W. Blattner, and The Brazilian ATLL Study Group. 1999. Geographic diversity of adult T-cell leukemia/lymphoma in Brazil. Int. J. Cancer 83:291298.
21. Tuke, P. W.,, P. Luton, and , J. A. Garson. 1992. Differential diagnosis of HTLV-I and HTLV-II infections by restriction enzyme analysis of ’nested’ PCR products. J. Virol. Methods 40:163173.
22. Vandamme, A. M.,, K. Van Laethem,, H. F. Liu,, M. Van Brussel,, F. Delaporte,, C. M. de Castro Costa,, C. Fleischer,, G. Taylor,, U. Bertazzoni,, J. Desmyter, and , P. Goubau. 1997. Use of a generic polymerase chain reaction assay detecting human T-lymphotropic virus (HTLV) types I, II and divergent simian strains in the evaluation of individuals with indeterminate HTLV serology. J. Med. Virol. 52:17.

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error